152 related articles for article (PubMed ID: 28438191)
1. Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.
Malik F; Ali N; Jafri SIM; Ghani A; Hamid M; Boigon M; Fidler C
J Med Case Rep; 2017 Apr; 11(1):119. PubMed ID: 28438191
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of mast cell activation syndrome with sunitinib.
Afrin LB; Cichocki FM; Patel K; Molderings GJ
Eur J Haematol; 2015 Dec; 95(6):595-7. PubMed ID: 26072665
[TBL] [Abstract][Full Text] [Related]
4. Capitalizing on paradoxical activation of the mitogen-activated protein kinase pathway for treatment of Imatinib-resistant mast cell leukemia.
Wilhelm T; Toledo MAS; Simons I; Stuth C; Mohta V; Mülfarth R; Nitsche M; Maschke-Neuß K; Schmitz S; Kaiser A; Panse J; Christen D; Arock M; Zenke M; Huber M
Hematol Oncol; 2023 Aug; 41(3):520-534. PubMed ID: 36383121
[TBL] [Abstract][Full Text] [Related]
5. Mast Cells, Mastocytosis, and Related Disorders.
Theoharides TC; Valent P; Akin C
N Engl J Med; 2015 Jul; 373(2):163-72. PubMed ID: 26154789
[No Abstract] [Full Text] [Related]
6. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
[TBL] [Abstract][Full Text] [Related]
7. H1-antihistamines for primary mast cell activation syndromes: a systematic review.
Nurmatov UB; Rhatigan E; Simons FE; Sheikh A
Allergy; 2015 Sep; 70(9):1052-61. PubMed ID: 26095756
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.
Marton I; Pósfai É; Borbényi Z; Bödör C; Papp G; Demeter J; Korom I; Varga E; Bata-Csörgő Z
Eur Rev Med Pharmacol Sci; 2015; 19(9):1607-9. PubMed ID: 26004600
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
Jensen BM; Akin C; Gilfillan AM
Br J Pharmacol; 2008 Aug; 154(8):1572-82. PubMed ID: 18500355
[TBL] [Abstract][Full Text] [Related]
10. Diphenhydramine may be useful as a palliative treatment for patients dying with Parkinson's disease and tremors: a case report and discussion.
Gonzalez F
Am J Hosp Palliat Care; 2009 Dec-2010 Jan; 26(6):474-5. PubMed ID: 19700649
[TBL] [Abstract][Full Text] [Related]
11. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
12. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.
Wasserman MJ; Weber DA; Guthrie JA; Bykerk VP; Lee P; Keystone EC
J Rheumatol; 2004 Oct; 31(10):1912-7. PubMed ID: 15468353
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Treatment of systemic mastocytosis with sunitinib.
Molderings GJ; Afrin LB; Hertfelder HJ; Brettner S
F1000Res; 2017; 6():2182. PubMed ID: 29770197
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations underlying eosinophilic and mast cell malignancies.
Sadrzadeh H; Abdel-Wahab O; Fathi AT
Discov Med; 2011 Dec; 12(67):481-93. PubMed ID: 22204765
[TBL] [Abstract][Full Text] [Related]
15. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
16. Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.
Kobayashi M; Kuroki S; Tanaka Y; Moriya Y; Kozutumi Y; Uehara Y; Ono K; Tamura K; Washizu T; Bonkobara M
Eur J Haematol; 2015 Dec; 95(6):524-31. PubMed ID: 25684098
[TBL] [Abstract][Full Text] [Related]
17. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
18. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
19. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
